Kiora Pharmaceuticals Inc Share Price Today: Live Updates & Key Insights

Kiora Pharmaceuticals Inc share price today is $2.06, up 2.96%. The stock opened at $2.02 against the previous close of $2.03, with an intraday high of $2.06 and low of $2.01.

Kiora Pharmaceuticals Inc Share Price Chart

Kiora Pharmaceuticals Inc

us-stock
To Invest in {{usstockname}}
us-stock

Kiora Pharmaceuticals Inc Share Price Performance

$2.06 0.0296(2.96%) KPRX at 23 Mar 2026 01:53 PM Biotechnology
Lowest Today 2.01
Highest Today 2.06
Today’s Open 2.02
Prev. Close 2.03
52 Week High 4.18
52 Week Low 1.77
Day’s Range: Low 2.01 High 2.06
52-Week Range: Low 1.77 High 4.18
1 day return -
1 Week return -
1 month return +2.48
3 month return -4.62
6 month return -21.07
1 year return -30.87
3 year return -93.69
5 year return -99.89
10 year return -

Kiora Pharmaceuticals Inc Institutional Holdings

ADAR1 Capital Management LLC 4.57

Stonepine Capital Management Llc 3.57

Nantahala Capital Management, LLC 2.89

Alyeska Investment Group, L.P. 2.09

DRW Securities, LLC 1.00

Vanguard Group Inc 0.90

Citadel Advisors Llc 0.61

Geode Capital Management, LLC 0.60

Renaissance Technologies Corp 0.58

Vanguard Institutional Extnd Mkt Idx Tr 0.54

Fidelity Extended Market Index 0.44

Citigroup Inc 0.11

Fidelity Series Total Market Index 0.09

Northern Trust Extended Eq Market Idx 0.07

NT Ext Equity Mkt Idx Fd - L 0.07

Bridgeway Omni Small-Cap Value 0.05

Bridgeway Omni Small-Cap Value N 0.05

Tower Research Capital LLC 0.04

Spartan Total Market Index Pool G 0.04

UBS Group AG 0.04

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.03

MILLER WEALTH ADVISORS, LLC 0.03

Fidelity Total Market Index 0.02

SBI Securities Co Ltd 0.01

Vanguard U.S. Eq Idx £ Acc 0.01

BlackRock Inc 0.00

Spartan Extended Market Index Pool F 0.00

Bank of America Corp 0.00

Goss Wealth Management LLC 0.00

NT Ext Equity Mkt Idx Fd - NL 0.00

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.00

Activest Wealth Management 0.00

Advisor Group Holdings, Inc. 0.00

SSgA U.S. Total Market Index Strategy 0.00

State St US Extended Mkt Indx NL Cl C 0.00

Velan Capital Investment Management LP 0.00

Kiora Pharmaceuticals Inc Market Status

Strong Buy: 0

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Kiora Pharmaceuticals Inc Fundamentals

Market Cap 7.69 M

PB Ratio 0.343

PE Ratio 0.0

Enterprise Value -11.28 M

Total Assets 36.48 M

Volume 55742

Kiora Pharmaceuticals Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:12059 0.0M, FY19:2686000 2.7M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:12059 0.0M, FY19:2686000 2.7M

Annual Net worth FY23:-12743736 -12.7M, FY22:-13583610 -13.6M, FY21:-16394919 -16.4M, FY20:-8091940 -8.1M, FY19:-7096696 -7.1M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:20000 0.0M

Quarterly Profit Q3/2025:-38235 -0.0M, Q2/2025:-31496 -0.0M, Q1/2025:-19608 -0.0M, Q3/2024:null 0.0M, Q2/2024:2123 0.0M

Quarterly Net worth Q3/2025:26806 0.0M, Q2/2025:-2152459 -2.2M, Q1/2025:-2192980 -2.2M, Q3/2024:-3413326 -3.4M, Q2/2024:-2221646 -2.2M

About Kiora Pharmaceuticals Inc & investment objective

Company Information Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301; and collaboration and development agreement with Global Genes for treating rare ocular disorders. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Organisation Biotechnology

Employees 12

Industry Biotechnology

CEO Dr. Brian M. Strem Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Kiora Pharmaceuticals Inc FAQs

What is the share price of Kiora Pharmaceuticals Inc today?

The current share price of Kiora Pharmaceuticals Inc is $2.06.

Can I buy Kiora Pharmaceuticals Inc shares in India?

Yes, Indian investors can buy Kiora Pharmaceuticals Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Kiora Pharmaceuticals Inc shares in India?

You can easily invest in Kiora Pharmaceuticals Inc shares from India by:

Can I buy fractional shares of Kiora Pharmaceuticals Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Kiora Pharmaceuticals Inc?

Kiora Pharmaceuticals Inc has a market cap of $7.69 M.

In which sector does Kiora Pharmaceuticals Inc belong?

Kiora Pharmaceuticals Inc operates in the Biotechnology sector.

What documents are required to invest in Kiora Pharmaceuticals Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Kiora Pharmaceuticals Inc?

The PE ratio of Kiora Pharmaceuticals Inc is N/A and the PB ratio is 0.34.